Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: The Hong Kong Diabetes Registry

Acta Diabetologica

Volumn 49, Issue 1 SUPPL., 2012, Pages

  Yang, Xilin ^a,b   So, Wing Yee ^a   Ma, Ronald C W ^a   Kong, Alice P S ^a   Lee, Heung Man ^a   Xu, Gang ^a   Ozaki, Risa ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; HDL cholesterol; LDL cholesterol; Triglyceride; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; MIDDLE AGED; NEOPLASM; RISK FACTOR;

AGED; ALBUMINURIA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HONG KONG; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TRIGLYCERIDES;

EID: 84878895163     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0409-y     Document Type: Article

References (45)

1. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH et al (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301(20):2129-2140
2. Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC et al (2008) Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 179(5):427-437
3. Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47(2):87-95
4. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M et al (2010) A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17(4):348-361
5. Jafri H, Alsheikh-Ali AA, Karas RH (2010) Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 55(25):2846-2854
6. Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP et al. (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. doi: 10.1007/s00592-011- 0361-2
7. Yang X, So WY, Ma RC, Ko GT, Kong AP, Wang Q et al (2008) Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 15(2):597-607
8. Yang X, So WY, Ma RC, Kong AP, Lee HM, Yu LW et al (2011) Low HDL cholesterol, metformin use and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 34(2):375-380
9. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH (2008) Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 50(5):409-418
10. Yang X, So WY, Ma RC, Ko GT, Kong AP, Zhao H et al (2009) Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 32(10):1826-1832
11. Yang X, Ma RC, So WY, Yu LW, Kong AP, Ko GT et al (2011) Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry. Cancer 117(4):862-871
12. Annunziata M, Granata R, Ghigo E (2011) The IGF system. Acta Diabetol 48(1):1-9
13. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96(24):13656-13661
14. Smith TM, Gilliland K, Clawson GA, Thiboutot D (2008) IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 128(5):1286-1293
15. Palozza P, Colangelo M, Simone R, Catalano A, Boninsegna A, Lanza P et al (2010) Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 31(10):1813-1821
16. Yang X, So WY, Ma RC, Kong AP, Xu G, Chan JC (2012) Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. Diabetes Metab Res Rev. doi: 10.1002/dmrr2287
17. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116(12):3090-3100
18. Navab M, Anantharamaiah GM, Fogelman AM (2005) The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 15(4):158-161
19. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49(11):1603-1616
20. Nakamura M, Onoda T, Itai K, Ohsawa M, Satou K, Sakai T et al (2004) Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med 43(10):919-925
21. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M (1993) For the DiabCare Monitoring Group of the St. Vincent Declaration Steering Committee. Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabetic Med 10:371-377
22. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y et al (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17(10):2937-2944
23. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499-502
24. Yang X, So WY, Tong PC, Ma RC, Kong AP, Lam CW et al (2008) Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med 168(5):451-457
25. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A (2005) Calculating measures of biological interaction. Eur J Epidemiol 20(7):575-579
26. Li R, Chambless L (2007) Test for additive interaction in proportional hazards models. Ann Epidemiol 17(3):227-236
27. Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP et al (2010) Associations of hyperglycaemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59(5):1254-1260
28. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9):1620-1625
29. Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT et al (2009) Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 58(7):1518-1525
30. Yang X, Ma RC, So WY, Ko GT, Kong AP, Zhao H et al (2010) White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes. Diabetes Res Clin Pract 87:117-125
31. Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP et al (2010) Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 90(3):343-351
32. Yang X, So WY, Ma RC, Yu LW, Kong AP, Lee HM, et al. (2012) Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Res Clin Pract. doi: 10.1016/jdiabres201203006
33. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC (2012) Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes Obes Metab 14(7):579-585
34. Godsland IF (2010) Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond) 118(5):315-332
35. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009) Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18(3):701-705
36. Brown KA, Simpson ER (2010) Obesity and breast cancer: progress to understanding the relationship. Cancer Res 70(1):4-7
37. Rothman KJ, Greenland S (2005) Causation and causal inference in epidemiology. Am J Public Health 95(Suppl 1):S144-S150
38. Johnson JA, Bowker SL (2010) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54(1):25-31
39. Yang XL, Ma RC, Chan JC (2011) Meta-analysis of trial data may support a causal role of hyperglycaemia in cancer. Diabetologia 54(3):709-710
40. Yamasaki K, Hayashi Y, Okamoto S, Osanai M, Lee GH (2010) Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice. Cancer Sci 101(1):65-72
41. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G et al (2001) Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 22(22):2075-2084
42. Singh BM, Mehta JL (2003) Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 163(11):1296-1304
43. Sui Y, Zhao HL, Ma RC, Ho CS, Kong AP, Lai FM et al (2007) Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy. Cell Mol Life Sci 64(23):3119-3128
44. Zhao HL, Sui Y, Guan J, He L, Zhu X, Fan RR et al (2008) Fat redistribution and adipocyte transformation in uninephrectomized rats. Kidney Int 74(4):467-477
45. Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89(3):331-340